|
25/11/2024
|
07:00
|
Truqap improved rPFS in advanced prostate cancer
|
RNS
|
|
20/11/2024
|
16:00
|
Director/PDMR Shareholding
|
RNS
|
|
18/11/2024
|
07:00
|
Tagrisso recommended for EU approval - LAURA
|
RNS
|
|
15/11/2024
|
14:00
|
Director/PDMR Shareholding
|
RNS
|
|
15/11/2024
|
10:00
|
Director/PDMR Shareholding
|
RNS
|
|
13/11/2024
|
16:00
|
Director/PDMR Shareholding
|
RNS
|
|
12/11/2024
|
07:10
|
AstraZeneca invests $3.5 billion in US
|
RNS
|
|
12/11/2024
|
07:05
|
KOMET Phase III trial met primary endpoint
|
RNS
|
|
12/11/2024
|
07:00
|
9M and Q3 2024 Results
|
RNS
|
|
12/11/2024
|
07:00
|
Dato-DXd new BLA submitted, NSQ BLA withdrawn
|
RNS
|
|
08/11/2024
|
07:00
|
Tezspire nasal polyps trial met primary endpoints
|
RNS
|
|
05/11/2024
|
16:49
|
AZN share price movement
|
RNS
|
|
01/11/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
30/10/2024
|
13:00
|
AZN China President under investigation
|
RNS
|
|
21/10/2024
|
07:00
|
Wainzua recommended for approval in the EU
|
RNS
|
|
07/10/2024
|
09:30
|
AstraZeneca licenses lipid lowering Lp(a) asset
|
RNS
|
|
01/10/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
26/09/2024
|
07:00
|
Tagrisso US approval in unresectable lung cancer
|
RNS
|
|
23/09/2024
|
07:05
|
Fasenra recommended for EU approval in EGPA
|
RNS
|
|
23/09/2024
|
07:00
|
Final OS results reported for TROPION-Breast01
|
RNS
|
|
20/09/2024
|
18:00
|
FluMist approved for self-administration in US
|
RNS
|
|
18/09/2024
|
07:00
|
Fasenra EGPA US FDA approval
|
RNS
|
|
13/09/2024
|
15:15
|
Director/PDMR Shareholding
|
RNS
|
|
02/09/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
16/08/2024
|
07:00
|
Imfinzi approved in US for resectable lung cancer
|
RNS
|
|
01/08/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
30/07/2024
|
07:00
|
AstraZeneca prices a €1.4bn bond offering
|
RNS
|
|
29/07/2024
|
08:41
|
Stabilisation Notice - ASTRAZENECA
|
RNS
|
|
29/07/2024
|
07:00
|
Calquence fixed-duration combo improved 1L CLL PFS
|
RNS
|
|
26/07/2024
|
07:00
|
ODAC reviewed Imfinzi in resectable lung cancer
|
RNS
|
|
25/07/2024
|
07:00
|
Half-year Report
|
RNS
|
|
15/07/2024
|
07:00
|
Acquisition of Amolyt Pharma completed
|
RNS
|
|
01/07/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
01/07/2024
|
07:00
|
Lynparza & Imfinzi positive CHMP in endometrial
|
RNS
|
|
25/06/2024
|
07:05
|
Update on Imfinzi ADJUVANT BR.31 trial
|
RNS
|
|
25/06/2024
|
07:00
|
Imfinzi improved EFS and OS in bladder cancer
|
RNS
|
|
18/06/2024
|
07:00
|
Update on CAPItello-290 Phase III trial
|
RNS
|
|
17/06/2024
|
07:00
|
Imfinzi approved in the US for endometrial cancer
|
RNS
|
|
12/06/2024
|
15:00
|
Director/PDMR Shareholding
|
RNS
|
|
05/06/2024
|
07:00
|
Acquisition of Fusion completed
|
RNS
|
|
03/06/2024
|
15:05
|
Block listing Interim Review
|
RNS
|
|
03/06/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
03/06/2024
|
07:00
|
Tagrisso plus chemo recommended for approval in EU
|
RNS
|
|
28/05/2024
|
07:00
|
Dato-DXd improved OS in nonsquamous lung cancer
|
RNS
|
|
21/05/2024
|
07:00
|
AstraZeneca to deliver $80bn revenue by 2030
|
RNS
|
|
20/05/2024
|
07:00
|
AstraZeneca to manufacture ADCs in Singapore
|
RNS
|
|
16/05/2024
|
07:00
|
SUPERNOVA Trial Met COVID-19 prevention endpoint
|
RNS
|
|
15/05/2024
|
15:00
|
Director/PDMR Shareholding
|
RNS
|
|
07/05/2024
|
07:00
|
AstraZeneca completes Cellectis equity investment
|
RNS
|
|
02/05/2024
|
07:00
|
Calquence combination improved PFS in 1L MCL
|
RNS
|